Novel hybrids with MAO and Aβ (1–42) self-aggregation inhibitory activities were designed and synthesized with the employment of indazole moiety and resveratrol. The biological screening results indicated that most compounds displayed potent inhibitory activity for Aβ (1–42) self-aggregation, and obvious selective inhibition to MAO-B. Among these compounds, compound 6e was the most potent inhibitor not only for hMAO-B (IC₅₀ = 1.14 μM) but also for Aβ (1–42) self-aggregation (58.9% at 20 μM). Molecular modeling and kinetic studies revealed that compound 6e was a competitive MAO-B inhibitor, which can occupy the active site of MAO-B, and interact with Aβ (1–42) via π-π and cation–π stacking interactions. In addition, compound 6e had no toxicity on PC12 cells and could cross the BBB. Collectively, all these results suggested that compound 6e might be a promising multi-target lead compound worthy of further investigation.

与MAO和一种新颖的杂种β（1-42）自聚集抑制活性，设计并与就业吲唑残基和白藜芦醇的合成。的生物筛选结果表明，大多数化合物显示出有效的抑制活性β（1-42）自聚集，和明显的选择性抑制对MAO-B。在这些化合物中，化合物6e中是最有效的抑制剂不仅用于ħ MAO-B（IC ₅₀  = 1.14μM），而且对于A β（1-42）自聚集（在20μM58.9％）。分子建模和动力学研究表明，化合物6e是一种竞争性MAO-B抑制剂，可占据MAO-B的活性位点并与A相互作用β（1–42）通过π - π和阳离子-π堆积相互作用。此外，化合物6e对PC12细胞无毒性，可以穿过血脑屏障。总的来说，所有这些结果表明化合物6e可能是一种有前途的多目标先导化合物，值得进一步研究。